Last $26.73 USD
Change Today -0.67 / -2.46%
Volume 1.1M
THOR On Other Exchanges
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

thoratec corp (THOR) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/31/13 - $43.58
52 Week Low
08/7/14 - $22.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THORATEC CORP (THOR)

thoratec corp (THOR) Related Businessweek News

No Related Businessweek News Found

thoratec corp (THOR) Details

Thoratec Corporation develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. The company’s primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure; and PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. In addition, the company provides Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising home discharge and post-cardiotomy myocardial recovery. It sells its products through direct sales force and distributors in the United States and internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.

951 Employees
Last Reported Date: 02/18/14
Founded in 1976

thoratec corp (THOR) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $302.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $338.3K
Total Annual Compensation: $570.7K
Compensation as of Fiscal Year 2013.

thoratec corp (THOR) Key Developments

Thoratec Corp. Approves and Adopts an Amended and Restated Version of its Bylaws

Thoratec Corp. announced that on September 16, 2014, the board approved and adopted an amended and restated version of the company's bylaws. The amendments added to the existing bylaws, among other things, procedures and informational requirements upon shareholders to propose business or nominations for election of directors to be considered at meetings of the company's shareholders as follows: require shareholders seeking to call a special meeting to provide a request stating the purpose of the meeting and providing information comparable to the requirements applicable to bring business before an annual meeting (Section 2); provide that the procedures and requirements set forth in the advance notice provisions are the only means for business to come before a shareholder meeting, other than matters properly brought under Rule 14a-8 of the Securities Exchange Act of 1934, as amended (Section 4(c)); require full disclosure of all ownership, derivative, economic and voting interests, hedges and economic incentives held by the shareholder proponent, any director nominee, and associated persons and any arrangements between such shareholders and nominees (Sections 4(d) and 4(e)); provide that persons are not eligible to serve as directors if not nominated in accordance with the advance notice provisions or appointed by the Board to fill a vacancy (Sections 4(e) and 4(f); and impose certain additional requirements for the valid nomination and election of board nominees (Section 4(f)).

Thoratec Provides Revenue Guidance for the Third Quarter of 2014

Thoratec provided revenue guidance for the third quarter of 2014. For the quarter, the company expected revenue in the range of $102 million to $107 million.

Thoratec Corporation Announces Management Changes

Thoratec Corporation announced that D. Keith Grossman has been appointed President and Chief Executive Officer, effective immediately. Mr. Grossman succeeds Gary F. Burbach, who has stepped down from his executive and Board roles but will remain as an advisor to the company through the first quarter of 2016. Mr. Grossman has served for 30 years in a variety of relevant healthcare industry roles, including as President and CEO of Thoratec from 1996 to 2006, a period in which the company pioneered the development of the mechanical circulatory support market and saw significant increases in both revenues and market value. Mr. Grossman has continued to serve on Thoratec's Board since that time. Most recently, he served as President and CEO of Conceptus Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THOR:US $26.73 USD -0.67

THOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $51.16 USD -1.66
Merit Medical Systems Inc $11.88 USD -0.12
NuVasive Inc $34.87 USD -0.15
Tornier NV $23.90 USD -0.22
Wright Medical Group Inc $30.30 USD -0.70
View Industry Companies

Industry Analysis


Industry Average

Valuation THOR Industry Range
Price/Earnings 23.5x
Price/Sales 3.1x
Price/Book 2.3x
Price/Cash Flow 22.8x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THORATEC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at